Dual-action power for transformative weight loss
A dual GIP and GLP-1 receptor agonist developed for diabetes and weight management.
Educational content. This page describes Tirzepatide for informational purposes only and is not medical advice, diagnosis, or treatment. Consult a licensed provider before starting, stopping, or modifying any therapy.
Improves blood pressure, triglycerides, and inflammatory markers, reducing predicted atherosclerotic cardiovascular risk.[7]
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Marketed as Mounjaro (for diabetes) and Zepbound (for obesity), it received FDA approval for type 2 diabetes in May 2022 and chronic weight management in November 2023.
The SURMOUNT-1 trial demonstrated unprecedented weight loss of up to 22.5%, approaching what was previously achievable only through bariatric surgery. This dual mechanism has generated significant scientific and clinical interest as a potential new standard of care.
Tirzepatide is a 39-amino acid synthetic peptide that activates both GIP and GLP-1 receptors. The GLP-1 component reduces appetite, slows gastric emptying, and enhances insulin secretion. The GIP component provides additional metabolic benefits that amplify these effects.
GIP receptor activation enhances fat metabolism, improves insulin sensitivity in adipose tissue, and may have direct effects on energy expenditure. Dual agonism leads to greater weight loss than GLP-1 alone through synergistic effects on appetite regulation and lipid metabolism.
Dual-action power for transformative weight loss
Tirzepatide simultaneously engages GIP and GLP-1 receptors, activating complementary cAMP signaling that enhances insulin secretion, suppresses glucagon, slows gastric emptying, reduces appetite, improves adipose insulin sensitivity, and enhances lipid metabolism — producing synergistic weight loss exceeding either pathway alone.
Key studies supporting the therapeutic use of this peptide.
Weight loss: 15.0% (5mg), 19.5% (10mg), 22.5% (15mg) vs 3.1% placebo at 72 weeks.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. — N Engl J Med, 387(3):205-216 (2022) · PubMed
Weight loss 12.8% (10mg) and 14.7% (15mg) vs 3.2% placebo, plus 2.1% HbA1c reduction.
Garvey WT, Frias JP, Jastreboff AM, et al. — Lancet, 402(10402):613-626 (2023) · PubMed
All tirzepatide doses superior to semaglutide 1mg for HbA1c and weight (-12.4kg vs -6.2kg).
Frias JP, Davies MJ, Rosenstock J, et al. — N Engl J Med, 385(6):503-515 (2021) · PubMed
Typical protocols used in clinical practice. Always consult a licensed provider for personalized dosing.
Subcutaneous Injection
Subcutaneous Injection: 20-week escalation: 2.5→5→7.5→10→12.5→15 mg
The 20-week dose escalation is essential to minimize GI side effects.
Inject in abdomen, thigh, or upper arm, rotating sites weekly.
If missed within 4 days, administer as soon as possible; if more than 4 days, skip to next scheduled dose.
Studied in over 10,000 participants across SURPASS and SURMOUNT programs. GI adverse events are most common, generally mild and transient during dose escalation.
Carries a boxed warning regarding thyroid C-cell tumors based on rodent studies. Contraindicated in patients with MTC or MEN2 history.
Use with caution in patients with severe GI disease, history of pancreatitis, or significant renal impairment. Discontinue at least one month before planned conception.
See how Tirzepatide compares to peptides with overlapping benefits.
| Peptide | Primary Use | Administration | Cycle Length | Key Differentiator |
|---|---|---|---|---|
| Tirzepatide | Weight Loss | Injection (weekly) | Ongoing | Only dual GIP/GLP-1 agonist, producing up to 22.5% weight loss — the highest of any pharmacotherapy |
| Semaglutide | Weight Loss | Injection (weekly), Oral (daily) | Ongoing | Most clinically validated weight-loss peptide with cardiovascular outcomes data from the SELECT trial |
| Tesamorelin | Body Composition & GHRH | Subcutaneous Injection | Ongoing daily | The only FDA-approved GHRH analog with Phase III data in over 800 patients, proven hepatoprotective effects, and physiologic pulsatile GH release |
| Ipamorelin | Anti-Aging & Body Composition | Injection (1-3x daily) | 8–12 weeks | Most selective GH secretagogue — clean pulsatile GH release without cortisol, prolactin, or appetite effects |
| AOD-9604 | Fat Reduction | Injection (daily) | 12-week cycles | GH's fat-burning effects without diabetogenic, anabolic, or IGF-1-elevating properties — though human trial efficacy was not demonstrated |
Current FDA classification and compounding eligibility.
This peptide is an FDA-approved drug available via standard prescription.
Dual GIP/GLP-1 receptor agonist. Approved as Mounjaro (2022, diabetes) and Zepbound (2023, weight management). On April 30, 2026 the FDA proposed removing tirzepatide from the 503B bulks list and tightened documentation requirements for 503A compounding. Public comment runs through June 29, 2026.
FDA proposed excluding tirzepatide from the 503B bulks list and clarified 503A documentation standards
FDA approved Zepbound (tirzepatide) for chronic weight management
FDA approved Mounjaro (tirzepatide) for type 2 diabetes
Last verified April 30, 2026. PepHookup tracks public FDA actions. This is not legal or medical advice.
Looking into Tirzepatide? Find a provider who knows this peptide and can walk you through your options.
Find a ProviderA GLP-1 receptor agonist that slows gastric emptying and reduces appetite signaling.
Approved as Ozempic and Wegovy for diabetes and chronic weight management; compounding increasingly restricted.
A stabilized 44-residue GHRH analog that stimulates endogenous growth hormone secretion.
FDA-approved as Egrifta for HIV-associated lipodystrophy; strongest clinical evidence of the GHRH analog family.
A selective ghrelin receptor agonist that prompts GH release without cortisol or prolactin effects.
Studied for body composition and recovery; ineligible for 503A compounding following the FDA PCAC safety review.